Revenue - Viatris Agreement (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Collaborative Arrangements and Co-Promote Agreement
Percentage of profit share	35.00%
Upfront payment receivable	$ 205,000
Collaboration revenue
Collaborative Arrangements and Co-Promote Agreement
Revenues	57,208	$ 48,654
Revefenacin Monotherapy (TD-4208)
Collaborative Arrangements and Co-Promote Agreement
Upfront payment receivable	160,000
Revefenacin Monotherapy (TD-4208) | Success Based Development Regulatory And Sales Milestones
Collaborative Arrangements and Co-Promote Agreement
Upfront payment receivable	10,000
Revefenacin Monotherapy (TD-4208) | Sales milestones
Collaborative Arrangements and Co-Promote Agreement
Upfront payment receivable	150,000
Future potential combination products
Collaborative Arrangements and Co-Promote Agreement
Upfront payment receivable	45,000
YUPELRI Monotherapy
Collaborative Arrangements and Co-Promote Agreement
Upfront payment receivable	$ 160,000
Viatris
Collaborative Arrangements and Co-Promote Agreement
Percentage of profit share	65.00%
Upfront payment receivable	$ 52,500
Viatris | Future potential combination products
Collaborative Arrangements and Co-Promote Agreement
Upfront payment receivable	$ 7,500
Viatris | YUPELRI Monotherapy
Collaborative Arrangements and Co-Promote Agreement
Percentage of profit share	35.00%	35.00%
Upfront payment receivable	$ 45,000
Revenues	77,337	$ 70,653
Viatris | YUPELRI Monotherapy | Success Based Development Regulatory And Sales Milestones
Collaborative Arrangements and Co-Promote Agreement
Upfront payment receivable	7,500
Viatris | YUPELRI Monotherapy | Sales milestones
Collaborative Arrangements and Co-Promote Agreement
Upfront payment receivable	37,500
Viatris | Collaborative Arrangement | Collaboration revenue
Collaborative Arrangements and Co-Promote Agreement
Revenues	57,201	48,624
Viatris | Royalties (Non-US) | Collaboration revenue
Collaborative Arrangements and Co-Promote Agreement
Revenues	$ 7	$ 30